Nanostics Inc.
Nanostics Inc.

John Lewis, CEO Frank & Carla Sojonky Chair in Prostate Cancer Research Associate Professor, Department of Oncology (University of Alberta)

Edmonton, Alberta

Nanostics Inc.

The Clarity DX, a new blood test to diagnose and predict prostate cancer.

Health Innovation

The Clarity DX is a new blood test to diagnose and predict prostate cancer. The test, which took five years to develop, is expected to be used on patients in Alberta as early as summer 2017.

How they are changing the world

John Lewis thanks a “perfect combination” of research, academic conditions, infrastructure, and philanthropic support.

Why Edmonton?

Prostate cancer is the most common cancer among men. Unfortunately, overdiagnosis and over treatment  are critical issues in prostate cancer screening. The Clarity DX aims to accurately find and pinpoint the disease early on to eliminate patients from having to undergo invasive tests and treatments. This test has the potential to save the health care system money.

What does the future look like?

Answers found unlocking this test may lead to ground-breaking tests for other cancers. John Lewis’ team is currently collaborating with others to come up with tests to better diagnose and predict ovarian and pancreatic cancers.

“This test requires just two drops of blood. It couldn’t be easier.”

Share This